3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
3
Genitourinary
2
Gastrointestinal
2
Thoracic
1
Gynecologic
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
21
Triple Negative Breast Neoplasms
6
Ovarian Neoplasms
6
Pancreatic Neoplasms
4
Neoplasm Metastasis
3
Neoplasms
2
Fallopian Tube Neoplasms
2
Urologic Neoplasms
1
Unilateral Breast Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neoplasm, Residual
1
Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
1
Melanoma
1
Lung Neoplasms
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
HER2-negative Metastatic Breast Cancer
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Interventions
pembrolizumab
19
Docetaxel
9
atezolizumab
8
Cetuximab
8
Nivolumab
7
cemiplimab
6
Ipilimumab
4
Immune Checkpoint Inhibitors
4
Gemcitabine
4
Drug Therapy
4
spartalizumab
3
palbociclib
3
fludarabine
3
durvalumab
3
avelumab
3
Trastuzumab
3
Radiotherapy
3
Paclitaxel
3
Oncolytic Virotherapy
3
Irinotecan
3
Fulvestrant
3
Fluorouracil
3
Cyclophosphamide
3
Carboplatin
3
Bortezomib
3
Blood Specimen Collection
3
seribantumab
2
selpercatinib
2
pazopanib
2
motexafin gadolinium
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
niraparib
×
Breast
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts